9月8日，Roivant Sciences盘中上涨14.2%，报39.9美元/股，成交额3711.26万美元。
消息面上，公司旗下Pulmovant部门宣布其吸入式sGC激活剂Mosliciguat在间质性肺病相关肺动脉高压（PH-ILD）患者中开展的二期PHocus研究达到主要及次要终点。数据显示，治疗16周后肺血管阻力经安慰剂校正降低56.3%，六分钟步行距离改善35.2米，NT-proBNP下降53.2%；在预设探索性分析中，24周时六分钟步行距离改善进一步扩大至52.7米，NT-proBNP降幅达75.9%。药物安全性良好，疗效持续改善。PH-ILD长期缺乏有效疗法，该数据为潜在突破。公司同时披露已启动Phrontier三期研究，推动Mosliciguat向注册阶段迈进。
Roivant Sciences是一家生物制药公司，核心管线包括处于FDA审查阶段的brepocitinib、靶向FcRn的IMVT-1402以及Mosliciguat。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.